InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 8 November 2023

Ardent: This study is evaluating how safe, tolerable and effective a new immunotherapy (called SC291) is when given after chemotherapy in people with relapsed and/or refractory B-cell cancersA Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Relapsed and/or Refractory B-cell Malignancies

Clinical summary

Summary

Eligible participants will receive a conditioning chemotherapy regimen of fludarabine and cyclophosphamide, followed by investigational treatment with SC291.

Conditions

This trial is treating patients with B-cell malignancies

Cancer

Blood Cancers Haematological

Age

People18 - 75

Phase

I

Trial Acronym

Ardent

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Sana Biotechnology

Scientific Title

A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Relapsed and/or Refractory B-cell Malignancies

Eligibility

Inclusion

  • Male or female subjects aged 18-75 years at the time of signing informed consent.
  • Diagnosis of NHL (WHO 2016 criteria) or CLL (iwCLL criteria), including:
  • Large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise - - specified (including DLBCL arising from indolent lymphoma), primary mediastinal large -- - B-cell lymphoma, high grade B-cell lymphoma, follicular lymphoma grade 3B
  • Follicular lymphoma (dose escalation only except for follicular lymphoma grade 3B)
  • Marginal zone lymphoma (dose escalation only)
  • Mantle cell lymphoma (dose escalation only)
  • CLL or SLL
  • Relapsed/refractory disease after at least 2 prior systemic regimens per standard of care or after autologous stem cell transplant
  • ECOG performance status of 0 or 1.
  • At least one measurable lesion per Lugano Classification (NHL); CLL subjects must meet iwCLL treatment criteria
  • Life expectancy ≥12 weeks

Exclusion

  • Prior anti-CD19 therapy including CD19-directed CAR T treatment or other CD19-directed antibody or cell therapy (e.g., NK cell). (Part 2 dose expansion only - prior approved CD19-directed CAR T therapy required)
  • History of primary central nervous system (CNS) lymphoma or presence of CNS metastases
  • Systemic anticancer therapy (including platinum-based chemotherapies and I/O therapies) or radiotherapy within 14 days of SC291 (28 days for biologics)
  • Autologous HSCT within 6 weeks of treatment with SC291 (or allogeneic HSCT at any time).
  • Active autoimmune disease or any other diseases requiring immunosuppressive therapy or corticosteroid therapy (defined as >20 mg/day prednisone or equivalent).
  • History or presence of cardiac or CNS disorders as defined in the protocol

Inclusion

  • You have had a certain type of treatment or surgical procedure.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

Exclusion

  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Cancer Connect

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Get support

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

More info for carers

CloseReport inaccuracy

Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.

HelpThis verification step helps prevent fraudulent transactions from automated software.
Submitting ... Please wait

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.